UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of February 2022
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Medicure Inc. |
| |
(Registrant) |
| |
|
| |
|
|
| Date: February 22, 2022 |
By: |
/s/ Dr. Albert D. Friesen |
| |
Dr. Albert D. Friesen |
| |
Title: CEO |
Exhibit 99.1
Medicure's Subsidiary - Marley Drug to Partner
with RxSpark, the Next Generation in Pharmacy Discount Programs, to be its Sole Mail-Order Pharmacy
WINNIPEG, MB, Feb. 22, 2022 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization
of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce the integration
of its subsidiary, Marley Drug® pharmacy, as the sole mail-order pharmacy for RxSpark™, the next generation
in pharmacy discount programs.
Described as a much-needed disruptor in the health
and pharmacy space, technology company RxSpark addresses an urgent need with its proprietary prescription drug savings program through
www.rxspark.com. Poor-coverage or lack of health insurance, exacerbated by the economic impact of the COVID-19 pandemic, has placed prescription
medication beyond the reach of many Americans. Additionally, the COVID-19 pandemic has accelerated changes to the healthcare system unlike
any other recent event, with increased consumer demand for online services such as telehealth, remote patient monitoring and home delivery
of medications. For its customers, the RxSpark platform offers a powerful search function and an improved drug results capacity which
makes it easier to find the best discounted prices for medications in nearby pharmacies throughout the U.S.
The integration of Marley Drug as the sole mail-order
pharmacy for the RxSpark platform now allows consumers using the platform to receive medication directly to their door. The Marley Drug
home delivery service will be available to all consumers regardless of where they may live in the U.S., as Marley Drug is licensed to
provide medication in all 50 states and most territories. Apart from the typical 30- and 90-day fill of medication, Marley Drug also offer
customers the ability to acquire extended supply fills of 6- and 12-months. For chronic care medication, 6- and 12-month quantities could
increase patient adherence and lead to better management of medical conditions. Additional benefits include fewer pharmacy visits, less
frequent refills and overall reduced cost. Marley Drug will provide well over 100 chronic care medications at $37 for 6-months and $70-for
12 months with free delivery anywhere in the United States and some territories.
Says Albert D. Friesen, PhD, Chief Executive Officer
of Medicure and Chair of its Board of Directors - "We are pleased to partner with RxSpark and to serve as the sole mail-order pharmacy
on the platform. Many Americans do not realize that prescription drug pricing can significantly vary from one pharmacy to another, and
even from day to day. However, having Marley Drug as a consistent option for affordable medication that is accessible by all Americans
regardless of where they may live, using the RxSpark platform, will provide a reasonable option for medication disparities. This is another
step forward to adapt to the rapidly changing health care landscape which places the consumer first, and it is also part of our broader
growth strategy, which recently included launching the Marley Drug Pharmacy e-commerce platform – www.marleydrug.com."
"In light of seismic changes to the health ecospace
and the shift to online services, we are excited to be partnering with Marley Drug to offer mail order medications to our members across
the whole of the U.S. Our goal has always been to improve access to affordable prescription medications and thereby encourage adherence
to treatment plans and contribute to a healthier America. Partnering with Marley Drug expands this offering, adding an affordable mail
order option to our prescription savings program," says John Casson, CEO and Founder of RxSpark.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the
development and commercialization of innovative and affordable therapeutics for the U.S. market. Medicure's sales force markets to physicians
and other healthcare professionals and now with E-Commerce integration, will be offering patients and providers direct online ordering
and home delivery. Our vision is to become a leading pharmaceutical company within the U.S, offering a growing portfolio of products that
improve patients' lives. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride)
injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure
Pharma Inc. Medicure also operates Marley Drug®, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers
an Extended Supply drug program serving all 50 states, Washington D.C. and most territories, including Puerto Rico. Marley Drug is committed
to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and
other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program
call 800.286.6781 or e-mail info@marleydrug.com. For more information on Medicure please visit https://www.medicure.com/. For additional
information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to
the full Prescribing Information.
To be added to Medicure's e-mail list, please visit: https://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
Forward Looking Information: Statements contained
in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates", "intends",
"expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian
and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred
to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the
Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors
which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown
risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or
developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements,
and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others,
the Company's future product revenues, expected results, including future revenue from the E-Commerce platform, expected future growth
in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials
and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon
collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry.
Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about:
general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's
revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development
projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability
of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and
demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company
undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other
than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company
and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2020.
View original content:https://www.prnewswire.com/news-releases/medicures-subsidiary---marley-drug-to-partner-with-rxspark-the-next-generation-in-pharmacy-discount-programs-to-be-its-sole-mail-order-pharmacy-301487410.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/February2022/22/c0037.html
%CIK: 0001133519
For further information: Dr. Albert D. Friesen, Chief Executive Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com , https://www.medicure.com/
CO: Medicure Inc.
CNW 09:00e 22-FEB-22
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medicure (PK) (USOTC:MCUJF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
